Literature DB >> 19005759

Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease.

R Aller1, D A de Luis, O Izaola, M Gonzalez Sagrado, R Conde, M C Velasco, T Alvarez, D Pacheco, J M González.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common liver disease. The aim of the present study was to explore the relation of visfatin with underlying histopathological changes of NAFLD patients.
SUBJECTS: A population of 55 NAFLD patients was analyzed in a cross-sectional study. A liver biopsy was realized. Weight, basal glucose, insulin, insulin resistance (HOMA), total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, and visfatin levels were measured. A bioimpedance was performed. RESULTS AND
CONCLUSIONS: The mean age was 42.8 +/- 11.2 years, the mean BMI was 33.1 +/- 10.2 with 37 males (67.3%) and 18 females (32.7%). Probabilities to have; portal inflammation increased 1.11 (CI95%:1.03-1.50) with each increment of 1 ng/ml of visfatin concentration, high grade of steatosis increased 1.25 (CI 95%:1.06-1.61) with each unit of insulin concentrations, fibrosis increased 1.12 (CI 95%:1.02-1.43) with each unit of fat mass and lobulillar inflammation increased 13.4 (CI 95%:1.3-147) with each unit of HOMA-IR. Portal inflammation frequencies were different between groups (low visfatin group 13.07 < ng/ml: 37.5% versus high visfatin group 13.07 > ng/ml: 62.5%; P < 0.05). In conclusion, several histopathological changes in liver biopsies could be explained by insulin concentrations, HOMA-IR, and fat mass amount. Moreover, visfatin plasma concentrations could predict the presence of portal inflammation in NAFLD patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005759     DOI: 10.1007/s10620-008-0539-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  19 in total

1.  Standards of medical care in diabetes--2007.

Authors: 
Journal:  Diabetes Care       Date:  2007-01       Impact factor: 19.112

2.  Genomic organization of the gene coding for human pre-B-cell colony enhancing factor and expression in human fetal membranes.

Authors:  S Ognjanovic; S Bao; S Y Yamamoto; J Garibay-Tupas; B Samal; G D Bryant-Greenwood
Journal:  J Mol Endocrinol       Date:  2001-04       Impact factor: 5.098

3.  Plasma visfatin concentrations and fat depot-specific mRNA expression in humans.

Authors:  Janin Berndt; Nora Klöting; Susan Kralisch; Peter Kovacs; Mathias Fasshauer; Michael R Schön; Michael Stumvoll; Matthias Blüher
Journal:  Diabetes       Date:  2005-10       Impact factor: 9.461

Review 4.  Nonalcoholic steatohepatitis: definition and pathology.

Authors:  E M Brunt
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

5.  Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance.

Authors:  Teoman Dogru; Alper Sonmez; Ilker Tasci; Ergun Bozoglu; Mahmut Ilker Yilmaz; Halil Genc; Gokhan Erdem; Mahmut Gok; Necati Bingol; Selim Kilic; Taner Ozgurtas; Sezin Bingol
Journal:  Diabetes Res Clin Pract       Date:  2006-09-07       Impact factor: 5.602

6.  Insulin sensitivity and hepatic steatosis in obese subjects with normal glucose tolerance.

Authors:  C Venturi; G Zoppini; C Zamboni; M Muggeo
Journal:  Nutr Metab Cardiovasc Dis       Date:  2004-08       Impact factor: 4.222

7.  Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study.

Authors:  A Pfützner; M Hanefeld; G Lübben; M M Weber; E Karagiannis; C Köhler; C Hohberg; T Forst
Journal:  Horm Metab Res       Date:  2007-10       Impact factor: 2.936

8.  Correlation of circulating full-length visfatin (PBEF/NAMPT) with metabolic parameters in subjects with and without diabetes: a cross-sectional study.

Authors:  Ravi Retnakaran; Byung-Soo Youn; Ying Liu; Anthony J G Hanley; Nam Seok Lee; Ji Woo Park; Eun Sun Song; Vivian Vu; Wi Kim; Rungsunn Tungtrongchitr; Peter J Havel; Michael M Swarbrick; Collin Shaw; Gary Sweeney
Journal:  Clin Endocrinol (Oxf)       Date:  2008-04-10       Impact factor: 3.478

9.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

Authors:  J Ludwig; T R Viggiano; D B McGill; B J Oh
Journal:  Mayo Clin Proc       Date:  1980-07       Impact factor: 7.616

Review 10.  Pathologic assessment of non-alcoholic fatty liver disease.

Authors:  Silvia Bondini; David E Kleiner; Zachary D Goodman; Terry Gramlich; Zobair M Younossi
Journal:  Clin Liver Dis       Date:  2007-02       Impact factor: 6.126

View more
  23 in total

1.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

2.  Visfatin, glucose metabolism and vascular disease: a review of evidence.

Authors:  Pedro Saddi-Rosa; Carolina S V Oliveira; Fernando M A Giuffrida; André F Reis
Journal:  Diabetol Metab Syndr       Date:  2010-03-26       Impact factor: 3.320

Review 3.  Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease.

Authors:  Sanja Stojsavljević; Marija Gomerčić Palčić; Lucija Virović Jukić; Lea Smirčić Duvnjak; Marko Duvnjak
Journal:  World J Gastroenterol       Date:  2014-12-28       Impact factor: 5.742

Review 4.  Potential role of leptin, adiponectin and three novel adipokines--visfatin, chemerin and vaspin--in chronic hepatitis.

Authors:  Michał Kukla; Włodzimierz Mazur; Rafał J Bułdak; Krystyna Zwirska-Korczala
Journal:  Mol Med       Date:  2011-07-05       Impact factor: 6.354

5.  The relationship between visfatin, liver inflammation, and acute phase reactants in chronic viral hepatitis B.

Authors:  Enver Yüksel; Erdem Akbal; Erdem Koçak; Ömer Akyürek; Seyfettin Köklü; Fuat Ekiz; Barış Yılmaz
Journal:  Wien Klin Wochenschr       Date:  2015-04-09       Impact factor: 1.704

6.  Visfatin levels in nonalcoholic fatty liver disease.

Authors:  Erdem Akbal; Erdem Koçak; Adnan Taş; Enver Yüksel; Seyfettin Köklü
Journal:  J Clin Lab Anal       Date:  2012-02       Impact factor: 2.352

Review 7.  Physiological and pathophysiological roles of NAMPT and NAD metabolism.

Authors:  Antje Garten; Susanne Schuster; Melanie Penke; Theresa Gorski; Tommaso de Giorgis; Wieland Kiess
Journal:  Nat Rev Endocrinol       Date:  2015-07-28       Impact factor: 43.330

Review 8.  Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations.

Authors:  Sandra Milić; Davorka Lulić; Davor Štimac
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

9.  Visfatin is regulated by rosiglitazone in type 2 diabetes mellitus and influenced by NFκB and JNK in human abdominal subcutaneous adipocytes.

Authors:  Kirsty C McGee; Alison L Harte; Nancy F da Silva; Nasser Al-Daghri; Steven J Creely; Christine M Kusminski; Gyanendra Tripathi; Paul L Levick; Manish Khanolkar; Marc Evans; Madhu V Chittari; Vinod Patel; Sudhesh Kumar; Philip G McTernan
Journal:  PLoS One       Date:  2011-06-09       Impact factor: 3.240

10.  Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH.

Authors:  Min Yong Yoon; Jun Mo Sung; Chang Seok Song; Won Young Lee; Eun Jung Rhee; Jun Ho Shin; Chang Hak Yoo; Seoung Wan Chae; Ja Yeon Kim; Wook Jin; Yong Kyun Cho
Journal:  Clin Mol Hepatol       Date:  2012-09-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.